Associate Prof. Osamu Kikuchi｜Division of Clinical Pharmacology and Cancer Immunotherapy｜Research Divisions, Labs & Researchers｜Research｜Center for Cancer Immunotherapy and Immunobiology

Education

1998-2004: School of Medicine, Kyoto University
2012-2016: Graduate School of Medicine, Kyoto University

Professional Experiences

2004-2006: Resident Fellow in Internal Medicine, The Tazuke-Kofukai, Medical Research Institute and Kitano Hospital, Osaka, Japan
2006-2009: Clinical Fellow, Department of Gastroenterology, Kurashiki Central Hospital, Okayama, Japan
2009-2012: Staff Physician, Department of Gastroenterology, Kurashiki Central Hospital, Okayama, Japan
2016/4-2016/10: Clinical Fellow, Department of Therapeutic Oncology, Kyoto University Hospital, Kyoto, Japan
2016-2019: Research Fellow, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
2019/10-2019/12: Clinical Fellow, Department of Therapeutic Oncology, Kyoto University Hospital, Kyoto, Japan
2020/1-2020/6: Assistant Professor, Clinical Bio-Resource Center, Kyoto University Hospital, Kyoto, Japan
2020/7-2023/5: Assistant Professor, Clinical Oncology, Kyoto University Hospital, Kyoto, Japan
2023/6~: Associate Professor, Division of Clinical Pharmacology and Immunotherapy, Center for Cancer Immunotherapy and Immunobiology (CC)), Kyoto University

Memberships

Japanese Society of Internal Medicine (2004-)
Japanese Society of Gastroenterology (2006-)
Japanese Gastroenterological Endoscopy Society (2006-)
The Japan Esophageal Society (2007-)
Japanese Society of Medical Oncology (2013-)
Japanese Cancer Association (2013-)
American Association for Cancer Research (2015-)
American Gastroenterological Association (2019-)

Awards

2014.4: JSPS Research Fellowships for Young Scientists (DC2)
2016.2: Scholarship by the Kyoto University Foundation
2016.11: International scholarship by Mochida Memorial Foundation for Medical and Pharmaceutical Research
2022.3: JSPS 13th HOPE Meeting

Grants & Collaborative Research

Grant-in-Aid for Early-Career Scientists: “Development of ferroptosis induction therapy targeting supraphysiological activation of KRAS in KRAS-amplified gastric cancer” (Principal Investigator, 20K16413, 2020/4-2023/3, Japan Society for the Promotion of Science (JSPS))
Open Innovation Preclinical Toolbox: “Exploring a combination therapy with Wee1 inhibitor and chemotherapeutic drugs against esophageal squamous cell carcinoma” (Principal Investigator, 2022/10-2024/9, AstraZeneca plc)
Collaborative Research “Development of novel treatment strategy against esophageal cancer” (Co-Investigator, 2022/10-2025/9, Taiho Pharmaceutical, Inc)
Grant-in-Aid for Early-Career Scientists: “Exploring the mechanism of the Sprouty pathway and development of molecular target therapy in KRAS-amplified gastric cancer” (Principal Investigator, 23K14617, 2023/4-2026/3, Japan Society for the Promotion of Science)

Selected Publications

Nguyen Vu TH, Kikuchi O, Ohashi S, Saito T, Ida T, Nakai Y, Cao Y, Yamamoto Y, Kondo Y, Mitani Y, Kataoka S, Kondo T, Katada C, Yamada A, Matsubara J, Muto M. Combination therapy with WEE1 inhibition and trifluridine/tipiracil against esophageal squamous cell carcinoma. Cancer Sci. 2023 Dec;114(12):4664-4676. https://doi.org/10.1111/cas.15966. Epub 2023 Sep 19. PMID: 37724648; PMCID: PMC10728021.

Jo, N., Hidaka, Y., Kikuchi, O., Fukahori, M., Sawada, T., Aoki, M., Yamamoto, M., Nagao, M., Morita, S., Nakajima, T., Muto, M., & Hamazaki, Y. (2023). Impaired CD4+ T cell response in older adults is associated with reduced immunogenicity and reactogenicity of mRNA COVID-19 vaccination. Nature Aging, 3(1), 82-92. https://doi.org/10.1038/s43587-022-00343-4

Li, T., Kikuchi, O. (Co-corresponding author), Zhou, J., Wang, Y., Pokharel, B., Bastl, K., Gokhale, P., Knott, A., Zhang, Y., Doench, J. G., Ho, Z. V., Catenacci, D. V., & Bass, A. J. (2023). Developing SHP2-based combination therapy for KRAS-amplified cancer. JCI Insight, 8(3), e152714. https://doi.org/10.1172/jci.insight.152714

Abe, T., Horisawa, Y., Kikuchi, O., Ozawa-Umeta, H., Kishimoto, A., Katsuura, Y., Imaizumi, A., Hashimoto, T., Shirakawa, K., Takaori-Kondo, A., Yusa, K., Asakura, T., Kakeya, H., & Kanai, M. (2022). Pharmacologic characterization of TBP1901, a prodrug form of aglycone curcumin, and CRISPR-Cas9 screen for therapeutic targets of aglycone curcumin. Eur J Pharmacol, 935, 175321. https://doi.org/10.1016/j.ejphar.2022.175321

Mitani, Y., Ohashi, S., Kikuchi, O., Nakai, Y., Ida, T., Mizumoto, A., Yamamoto, Y., Saito, T., Kataoka, S., Matsubara, J., Yamada, A., Kanai, M., Matsumoto, S., Sakai, H., Yoshikawa, K., Nakamura, E., & Muto, M. (2022). HER2 G776S mutation promotes oncogenic potential in colorectal cancer cells when accompanied by loss of APC function. Sci Rep, 12(1), 9213. https://doi.org/10.1038/s41598-022-13189-y

Mori, Y., Kikuchi, O., Horimatsu, T., Hara, H., Hironaka, S., Kojima, T., Kato, K., Tsushima, T., Ishihara, R., Mukai, K., Uozumi, R., Tada, H., Kasai, H., Kawaguchi, A., & Muto, M. (2022). Multicenter phase II study of trifluridine/tipiracil for esophageal squamous carcinoma refractory/intolerant to 5-fluorouracil, platinum compounds, and taxanes: the ECTAS study. Esophagus, 19(3), 444-451. https://doi.org/10.1007/s10388-021-00905-2

Ohashi, S., Maruno, T., Fukuyama, K., Kikuchi, O., Sunami, T., Kondo, Y., Imai, S., Matsushima, A., Suzuki, K., Usui, F., Yakami, M., Yamada, A., Isoda, H., Matsumoto, S., Seno, H., Muto, M., & Inoue, M. (2021). Visceral fat obesity is the key risk factor for the development of reflux erosive esophagitis in 40-69-years subjects. Esophagus, 18(4), 889-899. https://doi.org/10.1007/s10388-021-00859-5

Ohashi, S., Kikuchi, O., Nakai, Y., Ida, T., Saito, T., Kondo, Y., Yamamoto, Y., Mitani, Y., Nguyen Vu, T. H., Fukuyama, K., Tsukihara, H., Suzuki, N., & Muto, M. (2020). Synthetic Lethality with Trifluridine/Tipiracil and Checkpoint Kinase 1 Inhibitor for Esophageal Squamous Cell Carcinoma. Mol Cancer Ther, 19(6), 1363-1372. https://doi.org/10.1158/1535-7163.MCT-19-0918

Sethi, N. S., Kikuchi, O., Duronio, G. N., Stachler, M. D., McFarland, J. M., Ferrer-Luna, R., Zhang, Y., Bao, C., Bronson, R., Patil, D., Sanchez-Vega, F., Liu, J. B., Sicinska, E., Lazaro, J. B., Ligon, K. L., Beroukhim, R., & Bass, A. J. (2020). Early TP53 alterations engage environmental exposures to promote gastric premalignancy in an integrative mouse model. Nat Genet, 52(2), 219-230. https://doi.org/10.1038/s41588-019-0574-9

Kijima, T, Nakagawa, H, Shimonosono, M, Chandramouleeswaran, P M, Hara, T, Sahu, V, Kasagi, Y, Kikuchi, O, Tanaka, K, Giroux, V, Muir, A B, Whelan, K A, Ohashi, S, Naganuma, S, Klein-Szanto, A J, Shinden, Y, Sasaki, K, Omoto, I, Kita, Y, Muto, M, Bass, A J, Diehl, J A, Ginsberg, G G, Doki, Y, Mori, M, Uchikado, Y, Arigami, T, Avadhani, N G, Basu, D, Rustgi, A K and Natsugoe, S. Three-Dimensional Organoids Reveal Therapy Resistance of Esophageal and Oropharyngeal Squamous Cell Carcinoma Cells. Cell Mol Gastroenterol Hepatol 2019; 7(1): 73-91.

Mizumoto, A, Ohashi, S, Kamada, M, Saito, T, Nakai, Y, Baba, K, Hirohashi, K, Mitani, Y, Kikuchi, O, Matsubara, J, Yamada, A, Takahashi, T, Lee, H, Okuno, Y, Kanai, M and Muto, M. Combination treatment with highly bioavailable curcumin and NQO1 inhibitor exhibits potent antitumor effects on esophageal squamous cell carcinoma. J Gastroenterol 2019; 54(8): 687-698.

Nagaraja, A. K., Kikuchi, O., & Bass, A. J. (2019). Genomics and Targeted Therapies in Gastroesophageal Adenocarcinoma. Cancer Discov, 9(12), 1656-1672. DOI: https://doi.org/10.1158/2159-8290.Cd-19-0487

Sethi, N, Kikuchi, O (Co-corresponding author), McFarland, J, Zhang, Y, Chung, M, Kafker, N, Islam, M, Lampson, B, Chakraborty, A, Kaelin, W G, Jr. and Bass, A J. Mutant p53 induces a hypoxia transcriptional program in gastric and esophageal adenocarcinoma. JCI Insight 2019; 4(15): e128439.

Yoshioka, M, Ohashi, S, Ida, T, Nakai, Y, Kikuchi, O, Amanuma, Y, Matsubara, J, Yamada, A, Miyamoto, S, Natsuizaka, M, Nakagawa, H, Chiba, T, Seno, H and Muto, M. Distinct effects of EGFR inhibitors on epithelial- and mesenchymal-like esophageal squamous cell carcinoma cells. J Exp Clin Cancer Res 2017; 36(1): 101.

Kikuchi, O, Ohashi, S, Horibe, T, Kohno, M, Nakai, Y, Miyamoto, S, Chiba, T, Muto, M and Kawakami, K. Novel EGFR-targeted strategy with hybrid peptide against oesophageal squamous cell carcinoma. Sci Rep 2016; 6: 22452.

Kikuchi, O, Ohashi, S, Nakai, Y, Nakagawa, S, Matsuoka, K, Kobunai, T, Takechi, T, Amanuma, Y, Yoshioka, M, Ida, T, Yamamoto, Y, Okuno, Y, Miyamoto, S, Nakagawa, H, Matsubara, K, Chiba, T and Muto, M. Novel 5-fluorouracil-resistant human esophageal squamous cell carcinoma cells with dihydropyrimidine dehydrogenase overexpression. Am J Cancer Res 2015; 5(8): 2431-2440.

Ohashi, S, Miyamoto, S, Kikuchi, O, Goto, T, Amanuma, Y and Muto, M. Recent Advances From Basic and Clinical Studies of Esophageal Squamous Cell Carcinoma. Gastroenterology 2015; 149(7): 1700-1715.

Kikuchi, O, Ezoe, Y, Morita, S, Horimatsu, T and Muto, M. Narrow-band imaging for the head and neck region and the upper gastrointestinal tract. Jpn J Clin Oncol 2013; 43(5): 458-465.

Watanabe, T, Tsuji, Y, Takahashi, N, Yoshida, T, Tamaoki, M, Kikuchi, O, Watanabe, Y, Kodama, Y, Isoda, H, Yamamoto, H and Chiba, T. Relationship between pancreatic perfusion parameters and clinical complications of severe acute pancreatitis. Pancreas 2013; 42(1): 180-182.

Kikuchi, O, Mouri, H, Matsueda, K and Yamamoto, H. Endoscopic Submucosal Dissection for Treatment of Patients Aged 75 Years and over with Esophageal Cancer. ISRN Gastroenterol 2012; 2012: 671324.

Ohara, Y, Kikuchi, O, Goto, T, Yoshida, T, Mori, H, Matsueda, K and Yamamoto, H. Successful treatment of a patient with sepsis and liver abscess caused by Edwardsiella tarda. Internal medicine 2012; 51(19): 2813-2817.

Associate Professor Osamu Kikuchi Division of Clinical Pharmacology and Immunotherapy